Currently a patient receiving angioplasty is more likely to die from non-cardiac causes

Original title: Trends in cause of death after percutaneous coronary intervention. Reference: Spoon DB et al. Circulation. 2014; Epub ahead of print.

 

This retrospective study evaluated the specific cause of death in 19077patients who received angioplasty in a center between 1991 and 2008. To perform the analysis, the track was divided into three time periods: 1991-1996, 1997-2002, and 2003-2008. From all patients included, 6998 died at following up (37%, 4.48/100 patient-year) within which could determine the specific cause of death in 6857 (98.1 %). Cardiac mortality recorded for the period 1991-1996 was 9.8 %, decreasing to 7.4 % for 1997-2002 and finally 6.6 % for the last period, which means a 33% decrease in cardiac death within 5 years angioplasty index. Concomitantly, an increase of 57 % in the death of noncardiac causes (7.1 %, 8.5 % and 11.2 % respectively) was observed. Currently only 36.8% of patients receiving angioplasty die from cardiac causes, showing a similar trend in the different subgroups as elderly , magnitude of coronary disease and an indication for angioplasty (chronic angina or acute coronary syndrome). After adjusting all baseline variables, a decrease of 50 % in cardiac mortality over the years and a similar rate of non-cardiac deaths were observed. The decrease in cardiac death was due to a lower rate of fatal heart attacks and sudden death       (p < 0.001) but not heart failure deaths (p = 0.85). The increase in non- cardiac deaths was mainly due to cancer and other chronic diseases (p < 0.001).

Conclusion

This work showed a marked change in the last two decades regarding the cause of death in patients who received angioplasty (mainly cardiac to mainly non-cardiac). The reduction in cardiac death was independent of changes in baseline characteristics observed in the same period of time.

Editorial comment

The time periods for the division were chosen to correspond approximately to changes in the way angioplasties were performed: balloon angioplasty and provisional stenting in 1991-1996, routine angioplasty with conventional stent in 1997-2002 and conventional angioplasty with pharmacological stent 2003-2008. It is noteworthy that a death by heart failure has remained stable over time despite all pharmacological and devices advances.

SOLACI.ORG

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

Is left atrial appendage closure safe in patients with reduced ejection fraction?

Patients with heart failure with reduced ejection fraction (HFrEF) were excluded from the major randomized trials evaluating percutaneous left atrial appendage closure (LAAC), and...

Left Atrial Appendage Closure in Spain: Sustained Growth and Favorable Real-World Outcomes

Oral anticoagulation remains the standard treatment for stroke prevention in patients with atrial fibrillation. However, many patients have a high bleeding risk or contraindications...

HERA-TAVI: Intra-Annular vs Supra-Annular Valves in TAVI

The HERA-TAVI study is an international multicenter registry that compared the clinical and hemodynamic outcomes of contemporary self-expanding transcatheter heart valves with intra-annular (IA)...